253.28
price down icon0.25%   -0.63
after-market Handel nachbörslich: 253.81 0.53 +0.21%
loading
Schlusskurs vom Vortag:
$253.91
Offen:
$257.11
24-Stunden-Volumen:
9.27M
Relative Volume:
1.09
Marktkapitalisierung:
$610.38B
Einnahmen:
$97.93B
Nettoeinkommen (Verlust:
$21.04B
KGV:
29.36
EPS:
8.6278
Netto-Cashflow:
$17.80B
1W Leistung:
-1.25%
1M Leistung:
-5.21%
6M Leistung:
+6.12%
1J Leistung:
+32.49%
1-Tages-Spanne:
Value
$252.62
$262.44
1-Wochen-Bereich:
Value
$245.17
$264.39
52-Wochen-Spanne:
Value
$184.66
$281.07

Johnson Johnson Stock (JNJ) Company Profile

Name
Firmenname
Johnson Johnson
Name
Telefon
732-524-2455
Name
Adresse
ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK, NJ
Name
Mitarbeiter
140,800
Name
Twitter
@jnjnews
Name
Nächster Verdiensttermin
null
Name
Neueste SEC-Einreichungen
Name
JNJ's Discussions on Twitter

Compare JNJ vs LLY, ABBV, MRK, NVS

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
JNJ icon
JNJ
Johnson Johnson
253.28 610.38B 97.93B 21.04B 17.80B 8.6278
LLY icon
LLY
Lilly Eli Co
1,251.61 1.12T 72.25B 25.28B 10.37B 27.78
ABBV icon
ABBV
Abbvie Inc
283.40 500.80B 62.82B 3.60B 19.98B 2.0274
MRK icon
MRK
Merck Co Inc
145.19 358.21B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
150.38 285.83B 54.66B 13.58B 16.05B 7.0171

Johnson Johnson Stock (JNJ) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2026-09-02 Fortgesetzt UBS Buy
2026-05-13 Hochstufung Leerink Partners Market Perform → Outperform
2026-04-08 Fortgesetzt TD Cowen Buy
2026-01-28 Hochstufung Morgan Stanley Equal-Weight → Overweight
2025-11-13 Eingeleitet Scotiabank Sector Outperform
2025-10-20 Hochstufung Daiwa Securities Neutral → Outperform
2025-10-03 Hochstufung Wells Fargo Equal Weight → Overweight
2025-09-23 Hochstufung Guggenheim Neutral → Buy
2025-07-23 Hochstufung Erste Group Hold → Buy
2025-05-13 Herabstufung Leerink Partners Outperform → Market Perform
2024-12-10 Fortgesetzt BofA Securities Neutral
2024-11-15 Eingeleitet Wolfe Research Outperform
2024-07-23 Herabstufung Daiwa Securities Outperform → Neutral
2024-05-30 Fortgesetzt Goldman Neutral
2024-04-18 Hochstufung HSBC Securities Hold → Buy
2023-12-13 Herabstufung Wells Fargo Overweight → Equal Weight
2023-12-01 Hochstufung UBS Neutral → Buy
2023-10-05 Eingeleitet RBC Capital Mkts Outperform
2023-09-06 Eingeleitet HSBC Securities Hold
2023-05-30 Fortgesetzt Citigroup Buy
2023-03-29 Eingeleitet UBS Neutral
2023-03-01 Eingeleitet Guggenheim Neutral
2022-11-18 Eingeleitet Credit Suisse Neutral
2022-10-18 Eingeleitet Barclays Equal Weight
2022-10-14 Bestätigt BofA Securities Neutral
2022-06-22 Eingeleitet Daiwa Securities Outperform
2022-05-23 Fortgesetzt SVB Leerink Outperform
2022-04-06 Fortgesetzt Morgan Stanley Equal-Weight
2022-03-16 Herabstufung Bernstein Outperform → Mkt Perform
2022-03-02 Fortgesetzt BofA Securities Neutral
2021-12-17 Eingeleitet Goldman Neutral
2021-12-15 Bestätigt Citigroup Buy
2021-09-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-05-28 Fortgesetzt Morgan Stanley Overweight
2020-04-28 Herabstufung UBS Buy → Neutral
2020-04-22 Hochstufung BofA/Merrill Neutral → Buy
2020-03-05 Eingeleitet Citigroup Buy
2019-12-19 Hochstufung Barclays Equal Weight → Overweight
2019-12-17 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-11-20 Eingeleitet Cantor Fitzgerald Overweight
2019-10-16 Hochstufung Atlantic Equities Underweight → Neutral
2019-10-11 Hochstufung Bernstein Mkt Perform → Outperform
2019-07-12 Fortgesetzt Credit Suisse Outperform
2019-05-28 Eingeleitet Goldman Buy
2019-01-23 Bestätigt Barclays Equal Weight
2018-07-12 Hochstufung Goldman Sell → Neutral
2018-06-27 Eingeleitet Bernstein Mkt Perform
2018-04-23 Bestätigt Citigroup Neutral
2018-04-18 Bestätigt Stifel Hold
2018-01-24 Bestätigt Stifel Hold
2018-01-12 Bestätigt Wells Fargo Outperform
2018-01-02 Herabstufung JP Morgan Overweight → Neutral
2017-10-18 Bestätigt RBC Capital Mkts Outperform
2017-10-18 Bestätigt Stifel Hold
Alle ansehen

Johnson Johnson Aktie (JNJ) Neueste Nachrichten

pulisher
Oct 15, 2026

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today - Zacks Investment Research

Oct 15, 2026
pulisher
Oct 14, 2026

Which Pharma Stock Looks More Attractive: Sanofi or AbbVie? - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Why Did J&J Stock Fall After Q3 Earnings Despite Raised Guidance? - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Stock of the Day: Is this the Bottom for Johnson & Johnson? - TradingView

Oct 14, 2026
pulisher
Oct 14, 2026

The Open Question Under Johnson & Johnson Stock’s Price - Trefis

Oct 14, 2026
pulisher
Oct 14, 2026

Johnson & Johnson (JNJ) Stock Dropped, What Is Behind The Latest Attention? - Simply Wall Street

Oct 14, 2026
pulisher
Oct 14, 2026

J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says - 24/7 Wall St.

Oct 14, 2026
pulisher
Oct 14, 2026

JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Johnson & Johnson Reports Q3 2026 Results, Raises Full-Year Guidance - VisionMonday.com

Oct 14, 2026
pulisher
Oct 13, 2026

Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff, as Q3 device sales disappoint - MassDevice

Oct 13, 2026
pulisher
Oct 13, 2026

UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

UnitedHealth vs. Johnson & Johnson: Which Stock Is the Better Buy After Q3 Earnings? - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson: Keep Calm And Hold On (NYSE:JNJ) - Seeking Alpha

Oct 13, 2026
pulisher
Oct 13, 2026

J&J’s medtech business slows again in Q3 - MedTech Dive

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson shares fall following earnings - CNBC

Oct 13, 2026
pulisher
Oct 13, 2026

Why Johnson & Johnson Stock Dropped Today - The Motley Fool

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth - Morningstar

Oct 13, 2026
pulisher
Oct 13, 2026

Why Johnson & Johnson Stock Dropped Today - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson stock falls despite strong earnings as investors focus on medtech unit - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Stock Market Midday, Oct. 13: Bank Earnings and Chip Pressure Drive Mixed Trading - The Motley Fool

Oct 13, 2026
pulisher
Oct 13, 2026

What Johnson & Johnson (JNJ) Said on Its Q3 Earnings Call - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

J&J’s new pharma chief expects Icotyde’s psoriasis launch momentum to repeat across indications - Fierce Pharma

Oct 13, 2026
pulisher
Oct 13, 2026

Small-Business Optimism Dips in September - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

Mixed Pre-Markets Greet Fresh Q3 Earnings Reports - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson (JNJ) Reports 5.9% Revenue Growth, Plans Busin - GuruFocus

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson (JNJ) Q3 FY2026 earnings call transcript - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson (JNJ) Raises 2026 Sales and EPS Guidance After Q3 Beat - GuruFocus

Oct 13, 2026
pulisher
Oct 13, 2026

J&J's Tremfya posts forecast-topping quarter - FirstWord Pharma

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson Q3 Profit Plunges, Lifts FY26 Outlook; Stock Drops - RTTNews

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 - BioSpace

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson CFO Joseph Wolk on the company’s Q3 results - CNBC

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson raises profit guidance in Q3 2026 earnings - Quartz

Oct 13, 2026
pulisher
Oct 13, 2026

JOHNSON & JOHNSON ($JNJ) Releases Q3 2026 Earnings - Quiver Quantitative

Oct 13, 2026
pulisher
Oct 13, 2026

J&J beats earnings estimates; Middle East conflict weighs on medical device sales - Reuters

Oct 13, 2026
pulisher
Oct 13, 2026

J&J beats earnings estimates, eyes hip-knee unit spinoff by mid-2027 - CNBC

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson (JNJ) Q3 Earnings Surpass Estimates - Zacks Investment Research

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson and Johnson Earnings Report | 2026 Q3 Infographic - Johnson & Johnson

Oct 13, 2026
pulisher
Oct 13, 2026

J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business - WSJ

Oct 13, 2026
pulisher
Oct 13, 2026

J&J beats earnings estimates; Middle East conflict weighs on medical device sales - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance - Business Wire

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson (JNJ) Stock May Be 28% Undervalued As TREMFYA Data Impresses - Yahoo Finance

Oct 13, 2026
pulisher
Oct 13, 2026

Johnson & Johnson (JNJ) Stock May Be A Bargain Following New TREMFYA Trial Data - Simply Wall Street

Oct 13, 2026
pulisher
Oct 12, 2026

Want Passive Income for Life? Here Are 2 Dividend Stocks to Buy and Never Sell - The Motley Fool

Oct 12, 2026
pulisher
Oct 12, 2026

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Oct 12, 2026
pulisher
Oct 12, 2026

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Oct 12, 2026
pulisher
Oct 12, 2026

Johnson & Johnson earnings on deck: What to expect (JNJ:NYSE) - Seeking Alpha

Oct 12, 2026
pulisher
Oct 12, 2026

Middle East Tensions Rattle Markets - Zacks Investment Research

Oct 12, 2026
pulisher
Oct 12, 2026

Big Week of Data: Inflation & Q3 Earnings - Zacks Investment Research

Oct 12, 2026

Finanzdaten der Johnson Johnson-Aktie (JNJ)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Johnson Johnson-Aktie (JNJ) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Schmid Timothy
EVP, WW Chair, MedTech
Sep 02 '26
Sale
274.74
33,597
9,230,440
25,447
Schmid Timothy
Officer
Sep 02 '26
Proposed Sale
274.74
33,597
9,230,440
0
Taubert Jennifer L
EVP, WWC. Innovative Medicine
Aug 17 '26
Sale
263.36
15,000
3,950,400
194,451
Taubert Jennifer L
EVP, WWC. Innovative Medicine
Aug 17 '26
Option Exercise
115.67
15,000
1,735,050
209,451
Taubert Jennifer L
Officer
Aug 17 '26
Proposed Sale
263.36
15,000
3,950,418
0
Duato Joaquin
CEO and Chairman of the Board
Aug 13 '26
Option Exercise
115.67
123,291
14,261,070
399,258
Duato Joaquin
CEO and Chairman of the Board
Aug 13 '26
Sale
261.17
123,291
32,199,927
275,967
Duato Joaquin
Officer
Aug 13 '26
Proposed Sale
261.17
123,291
32,199,927
0
Forminard Elizabeth
EVP, Chief Legal Officer
Aug 06 '26
Option Exercise
131.94
9,344
1,232,847
32,912
Forminard Elizabeth
EVP, Chief Legal Officer
Aug 06 '26
Sale
257.00
15,918
4,090,960
16,994
$283.40
price down icon 0.03%
MRK MRK
$145.19
price down icon 1.48%
NVS NVS
$150.38
price up icon 2.38%
AZN AZN
$166.68
price up icon 2.87%
$434.03
price up icon 1.86%
$157.37
price up icon 2.49%
Kapitalisierung:     |  Volumen (24h):